Natural Capsules Earnings Call Transcript: Key Takeaways
Q2 revenue of ₹51.15 Cr (+12% YoY) and a narrower loss, but US capsule demand is absent, HPMC guidance is dropped, and FY27 API revenue guidance is cut to ₹12-15 Cr.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
13 announcements with these filters
Q2 revenue of ₹51.15 Cr (+12% YoY) and a narrower loss, but US capsule demand is absent, HPMC guidance is dropped, and FY27 API revenue guidance is cut to ₹12-15 Cr.
Q2FY27 revenue ₹51.15 Cr (+12% YoY), EBITDA ₹3.01 Cr (5.88% margin), still PAT loss ₹4.22 Cr. Strategy: API scale-up, regulatory filings, CMO expansion.
Natural Capsules issued a press release on its Q2 and H1 FY27 results, citing volume growth and API restructuring. Management expects EBITDA to hold steady.
Natural Capsules Ltd filed a corrigendum fixing a decimal error in six-month segment revenue (Capsules ₹9,050.16 Lakhs, API ₹936.31 Lakhs, total ₹9,986.47 Lakhs). The correction does not change reported results.
Natural Capsules allotted 1,12,500 equity shares to a single investor at Rs.178 each on a preferential basis. The allotment is worth about Rs.2.00 Crore.
Natural Capsules was fined ₹10,000 each by NSE and BSE for short board-meeting notice. The company has paid the fines and cited a late valuation report.
Natural Capsules Ltd reported revenue from operations of ₹51.1 Cr (+11.6% YoY) and a net loss of ₹4.2 Cr for Q2 FY27.
Natural Capsules added an allotment of 1,12,500 equity shares and 4,50,000 warrants to promoter Sunil Mundra to its 13 November board agenda. No issue price is stated.
Natural Capsules Limited has given prior intimation of a board meeting on 13 Nov 2026 to consider unaudited standalone and consolidated quarterly financial results for the period ended September 2026. The trading window closes from 01 Oct 2026 to 15 Nov 2026.
Natural Capsules clarifies the object of its ₹10.01 Crore preferential issue of shares and warrants. Proceeds fund working capital and capital expansion.
Natural Capsules Ltd dispatched a corrigendum to its upcoming EGM notice, revising the issue price and quantity for the proposed preferential allotment of shares and warrants.
Natural Capsules Limited approved a revised preferential issue of 1,12,500 equity shares and 4,50,000 convertible warrants. The total aggregate fund raise is valued at Rs. 10.01 Crore.
Natural Capsules Limited is holding a board meeting at shorter notice on September 02, 2026, to revise the issue price and quantity for its proposed preferential issue.